SEC Form 4 · accession 0001232524-18-000167
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director
Period of report
Sep 6, 2018
Accepted (ET)
Sep 7, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 6, 2018 | M | 3,415 | $143.66 | A | 19,884 | D | |
| Ordinary Shares | Sep 6, 2018 | M | 3,415 | $138.08 | A | 23,299 | D | |
| Ordinary Shares | Sep 6, 2018 | M | 3,300 | $135.44 | A | 26,599 | D | |
| Ordinary SharesF2 | Sep 6, 2018 | S | 2,044 | $167.9576 | D | 24,555 | D | |
| Ordinary SharesF3 | Sep 6, 2018 | S | 7,086 | $168.8633 | D | 17,469 | D | |
| Ordinary SharesF4 | Sep 6, 2018 | S | 1,000 | $169.694 | D | 16,469 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F5 | $135.44 | Sep 6, 2018 | M | 3,300 | D | — | Aug 6, 2024 | Ordinary Shares | 3,300 | 0 | D |
| Non-Qualified Stock Option (right to buy)F6 | $138.08 | Sep 6, 2018 | M | 3,415 | D | — | Aug 10, 2026 | Ordinary Shares | 3,415 | 0 | D |
| Non-Qualified Stock Option (right to buy)F7 | $143.66 | Sep 6, 2018 | M | 3,415 | D | — | Aug 9, 2027 | Ordinary Shares | 3,415 | 0 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $167.47 to $168.44. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $168.53 to $169.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $169.68 to $169.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5This non-qualified stock option was granted on August 7, 2014 and vested over a period of one year from August 1, 2014. The options were fully vested as of July 1, 2015.
- F6This non-qualified stock option was granted on August 11, 2016 and vested over a period of one year from September 1, 2016. The options were fully vested as of August 1, 2017.
- F7This non-qualified stock option was granted on August 10, 2017 and vested over a period of one year from September 1, 2017. The options were fully vested as of August 1, 2018.